Experiencia clínica en el tratamiento con mesalazina MMX en monoterapia en los pacientes con colitis ulcerosa

5-ASA are the first-line treatment of mild to moderate UC, the rectal being the most used for distal colitis and combination with oral formulations in the most extensive. Oral formulation is often patient preference and it affects crucially on patient adherence to the prescribed treatment. The MMX system allows the sustained release of the active ingredient throughout the colon allowing its use in monotherapy. A retrospective analysis was conducted to assess the degree of response to MMX mesalazine depending on the disease extension. At MMX mesalazine treatment beginning, 71% of patients had active UC and 29% were in remission. Regarding the extension, 31% of the cases were proctitis, 23% proctosigmoiditis and 46% left side colitis. The initial dose was 4.8 g/day in most active UC cases (54.4%) and 2.4 g/day (79.2%) in remission. After treatment initiation 55% resolved symptoms; no relation with the extension of the disease was observed.